stockrow
Friday 6 November 2026
Export GTBP’s income statement to Excel — free account
GT Biopharma, Inc.
GTBP Healthcare Biotechnology
- EPS
- +98.9%
- Free cash flow
- −41.3%
Quarter to June 2026, against a year earlier
4.42
0.12
−2.64%
Follow GTBP
Alert me
GT Biopharma, Inc. (GTBP) P/E ratio
As of 6 November 2026, GT Biopharma, Inc. (GTBP) trades at a P/E ratio of 0.8×. Over the past ten years it has ranged from 0.0× (June 2026) to 2.1× (July 2026); the current reading is higher than 97% of that period. That is below the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2015 | 0.0× | — |
| Jun 2015 | 0.4× | — |
| Mar 2015 | 0.0× | — |
Against its own ten years
Low 0.0×
High 2.1×
Ten-year median
0.0×
Current reading's percentile
97
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CALC CalciMedica Inc. compare | n/m |
| AEON AEON Biopharma, Inc. compare | n/m |
| CURX Curanex Pharmaceuticals Inc compare | n/m |
| PHIO Phio Pharmaceuticals Corp. compare | n/m |
| BLRX BioLineRx Ltd. compare | n/m |
| CMMB Chemomab Therapeutics Ltd. Sponsored ADR compare | n/m |
| AZR Azora Therapeutics, Inc. compare | n/m |
| MBRX Moleculin Biotech, Inc. compare | 0.0× |
| GTBP GT Biopharma, Inc. | 0.8× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)